CURRENT EYE RESEARCH, cilt.40, sa.6, ss.585-591, 2015 (SCI-Expanded)
Purpose: To evaluate the two-year follow-up of patients with type 1 retinopathy of prematurity (ROP) who received intravitreal bevacizumab (IVB) as adjunctive treatment.